Cosequin Helps Navicular Horses, Study Shows

A recently published clinical study conducted at Auburn University Equine Hospital supports the use of the nutraceutical product Cosequin in navicular syndrome cases.
Share
Favorite
Close

No account yet? Register

ADVERTISEMENT

A recently published clinical study conducted at Auburn University Equine Hospital supports the use of the nutraceutical product Cosequin in navicular syndrome cases. Cosequin is manufactured by Nutramax Laboratories.

Navicular syndrome (also known as podotrochleosis) is a significant cause of forelimb lameness in horses. This is a complex condition that involves pathology of the navicular bone, bursa (fluid-filled cushioning sac), and the portion of the deep digital flexor tendon in the area of the navicular bone and bursa. The navicular bone is a sesamoid bone lying beneath the deep digital flexor tendon and articulating with the middle and distal phalanx bones (P2 and P3); the joint space between P2 and P3 is the coffin joint. The deep digital flexor tendon glides over the fibrocartilage-covered surface of the navicular bone and its associated bursa.

The cause of navicular syndrome is not known, but the result is lameness. Many factors can cause the syndrome, such as small blood clots compromising blood flow to the navicular bone, trauma, and certain metabolic conditions. The bony changes seen with navicular syndrome and degenerative joint disease (DJD) are similar; hence it has been suggested that navicular disease be classified as a form of DJD. Because of this, therapies useful for DJD, which include hoof trimming, special shoeing, pharmacologic compounds, and non-pharmacologic nutraceutical agents that support and protect articular cartilage, might prove beneficial in treating navicular syndrome.

Cosequin is a patented formulation of FCHG49 glucosamine hydrochloride, TRH122 low-molecular-weight sodium chondroitin sulfate, and manganese ascorbate. Previous studies conducted at Auburn showed that Cosequin is effective in managing degenerative joint disease in the hock and coffin joint as well as ringbone. Recent cell culture studies conducted by investigators at other veterinary schools using equine cartilage have shown that Cosequin can inhibit the rate of cartilage breakdown. Also, research presented at the 2001 American Association of Equine Practitioners meeting showed Cosequin to be bioavailable in horses (meaning the horse can absorb and use the materials)

Create a free account with TheHorse.com to view this content.

TheHorse.com is home to thousands of free articles about horse health care. In order to access some of our exclusive free content, you must be signed into TheHorse.com.

Start your free account today!

Already have an account?
and continue reading.

Share

Written by:

R. Reid Hanson, DVM, Dipl. ACVS, joined the surgical faculty at Auburn University in 1992, and is currently a Professor of Equine Surgery and Lameness. He is the author of over 180 scientific articles, abstracts, presentations, and book chapters related to equine surgery, lameness and critical care. Dr. Hanson is also an award-winning speaker, speaking to international audiences about these important topics. In his free time he enjoys competitive swimming and training. More information on Dr. Hanson can be found at www.vetmed.auburn.edu/faculty.dcs-faculty/hanson.

Related Articles

Stay on top of the most recent Horse Health news with

FREE weekly newsletters from TheHorse.com

Sponsored Content

Weekly Poll

sponsored by:

When do you begin to prepare/stock up on products/purchase products for these skin issues?
100 votes · 100 answers

Readers’ Most Popular

Sign In

Don’t have an account? Register for a FREE account here.

Need to update your account?

You need to be logged in to fill out this form

Create a free account with TheHorse.com!